# Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

> **NCT03792490** · PHASE2 · COMPLETED · sponsor: **University Medical Center Goettingen** · enrollment: 120 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Fasudil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03792490
- **Lead sponsor:** University Medical Center Goettingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-11-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792490, "Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03792490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*